GGrantIndex
← Leaderboards

Tony P George

Yale University

$3,429,046
Attributed
$3,429,046
Total exposure
7
Grants
3
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $484.9K · FY200518
$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18

Funding mix

By agency

NIH$3,429,046 · 7

By mechanism

R01$2,538,322 · 3
K02$306,545 · 1
P50$298,168 · 2
R21$286,011 · 1

Top collaborators

No co-investigators on record.

Most similar at Yale University

Same institution · by research overlap

Others in their field

Top investigators on “Human Subject

Research focus

Human SubjectSmoking CessationHuman Therapy EvaluationUrinalysisSchizophreniaClinical ResearchBehavioral /Social Science Research TagDrug Abuse ChemotherapyClinical TrialsDrug WithdrawalQuestionnairesComorbidityLongitudinal Human StudyCounselingCravingTobacco AbusePatient Oriented ResearchBupropionSmokingNeuropsychological TestsAntipsychotic AgentsNicotineNicotine ReplacementCatecholamines

Grant awards (21)

Effects of rTMS on Cannabis Use and Cognitive Outcomes in Schizophrenia$130,374
R21 · FY2018 · DA · contact PI
Effects of rTMS on Cannabis Use and Cognitive Outcomes in Schizophrenia$155,637
R21 · FY2017 · DA · contact PI
Selegiline for Smoking Cessation$349,648
R01 · FY2006 · DA · contact PI
Translational Studies on Smoking in Schizophrenia$52,853
K02 · FY2006 · DA · contact PI
Selegiline for Smoking Cessation$358,063
R01 · FY2005 · DA
Translational Studies on Smoking in Schizophrenia$126,846
K02 · FY2005 · DA
Selegiline for Smoking Cessation$356,015
R01 · FY2004 · DA
Optimizing Treatment for Schizophrenic Smokers$211,950
R01 · FY2004 · DA
Translational Studies on Smoking in Schizophrenia$126,846
K02 · FY2004 · DA
Optimizing Treatment for Schizophrenic Smokers$211,950
R01 · FY2003 · DA
Nicotinic Receptors and Cog Function in Schizophrenia$211,331
R01 · FY2003 · DA
Optimizing Treatment for Schizophrenic Smokers$211,950
R01 · FY2002 · DA
Nicotinic Receptors and Cog Function in Schizophrenia$211,744
R01 · FY2002 · DA
PILOT STUDY--SELEGILINE FOR SMOKING CESSATION$0
P50 · FY2002 · DA
GABAERGIC &GLUTAMATERGIC AGENTS--COCAINE USE IN METHADONE MAINTENANCE$0
P50 · FY2002 · DA
Optimizing Treatment for Schizophrenic Smokers$211,950
R01 · FY2001 · DA
Nicotinic Receptors and Cog Function in Schizophrenia$203,721
R01 · FY2001 · DA
PILOT STUDY--SELEGILINE FOR SMOKING CESSATION$0
P50 · FY2001 · DA
GABAERGIC &GLUTAMATERGIC AGENTS--COCAINE USE IN METHADONE MAINTENANCE$0
P50 · FY2001 · DA
GABAERGIC &GLUTAMATERGIC AGENTS--COCAINE USE IN METHADONE MAINTENANCE$160,750
P50 · FY2000 · DA
PILOT STUDY--SELEGILINE FOR SMOKING CESSATION$137,418
P50 · FY2000 · DA